Published: Tue, May 09, 2017
Money | By Armando Alvarado

Endo International plc - (ENDP) Lifted to "Buy" at Vetr Inc

Endo International plc - (ENDP) Lifted to

COPYRIGHT VIOLATION NOTICE: "Endo International plc - (ENDP) Rating Increased to Hold at Zacks Investment Research" was originally published by Chaffey Breeze and is owned by of Chaffey Breeze.

The biggest institutional shareholders in Endo International plc include TPG Capital LP which owns 22 million shares in the company valued at $364.85 million. Currently Endo International plc (ENDP) has beta value of 0.56. Mizuho upped their target price on Endo International plc - to $17.00 in a report on Friday, March 3rd. For our stock under consideration here, Endo International plc (ENDP) has distance from 20 Day SMA is -1.78% while its distance from 50 day SMA is -2.25%. Thirteen analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company.

Now the shares of Endo International plc (ENDP) has a trading volume of 7.27 Million shares, with an average trading volume of 6780 shares - with shares dropping to a 52 week low of $9.70, and the company's shares hitting a 52 week high of $ 24.93. The stock, after opening at $11.21, closed at $10.85 by scoring -4.99%. -14.47 EPS for Endo International plc shows how profitable the company is alongside the other key metrics such as volatility. The firm has a 50-day moving average price of $10.88 and a 200-day moving average price of $13.92. On Wednesday, November 9 the stock rating was maintained by RBC Capital Markets with "Outperform".

Since the start of the New Year, Endo International plc (NASDAQ:ENDP) shares have seen a move of -30.66%. -EPS Growth (Y-o-Y): 13.9% -Analysts Estimate: $1.10 -Revenue (Q1): $1.04 Bln vs. $0.96 Bln previous year. Arizona State Retirement System has 0.01% invested in Endo International plc - Ordinary Shares (NASDAQ:ENDP). During the same period in the prior year, the firm posted $1.36 EPS. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.17 billion.

WARNING: This article was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of U.S. & worldwide copyright and trademark legislation. The correct version of this article can be read at https://www.themarketsdaily.com/2017/05/09/endo-international-plc-endp-upgraded-to-buy-by-vetr-inc-2.html. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Harvey suspended by Mets
NY also claimed lefty Tommy Milone off waivers from Milwaukee - he was 1-0 with one save and a 6.43 earned-run average. The 28-year-old has been disappointing on the mound as well this season with a 5.14 ERA through his first six starts.

A number of large investors have recently modified their holdings of ENDP. Finally, Ameriprise Financial Inc. raised its position in shares of Endo International plc - by 685.0% in the first quarter.

The company's expected revenue in the current quarter to be 1.02 Billion, seeing a projected current quarter growth of 1.9%, and per annum growth estimates over the next 5 year period of around -2.9%. Point View Wealth Management Inc. boosted its stake in Endo International plc - by 12.3% in the first quarter.

The Dublin-based company said it had a loss of 78 cents per share. Russell Investments Group Ltd. purchased a new stake in shares of Endo International plc - during the fourth quarter valued at about $3,711,000. Finally, Norges Bank purchased a new stake in shares of Endo International plc - during the fourth quarter worth about $26,929,000. Riverhead Capital Management LLC now owns 20,412 shares of the company's stock valued at $411,000 after buying an additional 15,704 shares during the period.

Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ's health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs.

Like this: